Antioxidant Treatment Rescues An Accelerated Aging Phenotype In Dyskerin Mutated Bone Marrow Stem Cells

Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized riboso...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 116; no. 21; p. 2614
Main Authors Gu, Baiwei, Fan, Jian-meng, Bessler, Monica, Mason, Philip J
Format Journal Article
LanguageEnglish
Published Elsevier Inc 19.11.2010
Online AccessGet full text
ISSN0006-4971
1528-0020
DOI10.1182/blood.V116.21.2614.2614

Cover

Abstract Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized ribosomal RNAs and spliceosomal snRNAs. Dyskerin also associates with telomerase and is involved in telomere maintenance. In addition to the well known effect of telomere homeostasis on cancer, it is evident that telomere maintenance may also be important in replicative aging because of telomere shortening due to the limited expression of telomerase activity in dividing somatic cells. Accumulating evidence suggests that dysfunctional telomeres resulting in premature cellular senescence is the primary cause of bone marrow failure in dyskeratosis congenita. It is important to determine the mechanism whereby Dkc1 mutations lead to premature cellular senescence in bone marrow. We have produced a line of mice containing a mutation, Dkc1Δ15, which is a copy of a pathogenic human mutation. Male Dkc1Δ15 mice showed a decrease in the proportion of B and T lymphocytes in peripheral blood and reduced body weight with age but no overt bone marrow failure syndrome phenotypes. Our previous competitive bone marrow transplantation experiments showed that the Dkc1Δ15 mutation caused decay of stem cell function with age. Bone marrow from older Dkc1Δ15 mice was markedly inefficient in repopulation studies compared with bone marrow from age matched wild type mice. We also found that N-acetyl cysteine (NAC) could at least partially rescue the growth disadvantage of dyskerin mutant spleen cells or fibroblasts which was associated with accumulation of DNA damage and reactive oxygen species. To determine if NAC, or other antioxidants might be useful therapeutically it is important to determine their effects on stem cell function, which is defective in DC. To this end we established a cohort of mice that were given NAC in their drinking water (1mg/ml) from 3-weeks of age and maintained on NAC for 1 year. We found that long term NAC treatment did not show significant side effects on the mice. They had slightly increased neutrophils, but no difference in life span and body weight compared with the untreated group. Impressively, old male Dkc1Δ15 mice showed corrected B and T cell proportions in peripheral blood after treatment with NAC. Competitive bone marrow transplantation experiments were carried out in which a 1:1 mixture of BM cells from mutant and WT mice was used to repopulated lethally irradiated recipient mice. These experiments showed that, when taken from NAC treated animals, old Dkc1Δ15 BM cells could compete with age matched WT cells with 40–45% of Dkc1Δ15 cells in primary recipients compared with only 20% for the untreated group. Moreover, after secondary transplantation, cells from the NAC treated group still represent 15–20% of Dkc1Δ15 cells in recipients while those from the untreated group could not be detected. These results strongly suggest that NAC treatment can partially restore the bone marrow repopulating ability of Dkc1Δ15 stem cells. Together with our previous results these data suggest that a pathogenic Dkc1 mutation, through its effect on telomerase, initiates stem cell aging before telomeres are short and that increased oxidative stress might play a role in this process. Moreover the effects of the mutation may be prevented or delayed by antioxidant treatment, although the precise mechanism will be the subject of future investigation. Bessler:Alexion Pharmaceutical Inc:Consultancy;Novartis: Membership on an entity's Board of Directors or advisory committees; Taligen: Consultancy.
AbstractList Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized ribosomal RNAs and spliceosomal snRNAs. Dyskerin also associates with telomerase and is involved in telomere maintenance. In addition to the well known effect of telomere homeostasis on cancer, it is evident that telomere maintenance may also be important in replicative aging because of telomere shortening due to the limited expression of telomerase activity in dividing somatic cells. Accumulating evidence suggests that dysfunctional telomeres resulting in premature cellular senescence is the primary cause of bone marrow failure in dyskeratosis congenita. It is important to determine the mechanism whereby Dkc1 mutations lead to premature cellular senescence in bone marrow. We have produced a line of mice containing a mutation, Dkc1Δ15, which is a copy of a pathogenic human mutation. Male Dkc1Δ15 mice showed a decrease in the proportion of B and T lymphocytes in peripheral blood and reduced body weight with age but no overt bone marrow failure syndrome phenotypes. Our previous competitive bone marrow transplantation experiments showed that the Dkc1Δ15 mutation caused decay of stem cell function with age. Bone marrow from older Dkc1Δ15 mice was markedly inefficient in repopulation studies compared with bone marrow from age matched wild type mice. We also found that N-acetyl cysteine (NAC) could at least partially rescue the growth disadvantage of dyskerin mutant spleen cells or fibroblasts which was associated with accumulation of DNA damage and reactive oxygen species. To determine if NAC, or other antioxidants might be useful therapeutically it is important to determine their effects on stem cell function, which is defective in DC. To this end we established a cohort of mice that were given NAC in their drinking water (1mg/ml) from 3-weeks of age and maintained on NAC for 1 year. We found that long term NAC treatment did not show significant side effects on the mice. They had slightly increased neutrophils, but no difference in life span and body weight compared with the untreated group. Impressively, old male Dkc1Δ15 mice showed corrected B and T cell proportions in peripheral blood after treatment with NAC. Competitive bone marrow transplantation experiments were carried out in which a 1:1 mixture of BM cells from mutant and WT mice was used to repopulated lethally irradiated recipient mice. These experiments showed that, when taken from NAC treated animals, old Dkc1Δ15 BM cells could compete with age matched WT cells with 40–45% of Dkc1Δ15 cells in primary recipients compared with only 20% for the untreated group. Moreover, after secondary transplantation, cells from the NAC treated group still represent 15–20% of Dkc1Δ15 cells in recipients while those from the untreated group could not be detected. These results strongly suggest that NAC treatment can partially restore the bone marrow repopulating ability of Dkc1Δ15 stem cells. Together with our previous results these data suggest that a pathogenic Dkc1 mutation, through its effect on telomerase, initiates stem cell aging before telomeres are short and that increased oxidative stress might play a role in this process. Moreover the effects of the mutation may be prevented or delayed by antioxidant treatment, although the precise mechanism will be the subject of future investigation.
Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved nucleolar protein that, as part of a specialized nucleolar RNP, catalyzes the pseudouridylation of specific residues in newly synthesized ribosomal RNAs and spliceosomal snRNAs. Dyskerin also associates with telomerase and is involved in telomere maintenance. In addition to the well known effect of telomere homeostasis on cancer, it is evident that telomere maintenance may also be important in replicative aging because of telomere shortening due to the limited expression of telomerase activity in dividing somatic cells. Accumulating evidence suggests that dysfunctional telomeres resulting in premature cellular senescence is the primary cause of bone marrow failure in dyskeratosis congenita. It is important to determine the mechanism whereby Dkc1 mutations lead to premature cellular senescence in bone marrow. We have produced a line of mice containing a mutation, Dkc1Δ15, which is a copy of a pathogenic human mutation. Male Dkc1Δ15 mice showed a decrease in the proportion of B and T lymphocytes in peripheral blood and reduced body weight with age but no overt bone marrow failure syndrome phenotypes. Our previous competitive bone marrow transplantation experiments showed that the Dkc1Δ15 mutation caused decay of stem cell function with age. Bone marrow from older Dkc1Δ15 mice was markedly inefficient in repopulation studies compared with bone marrow from age matched wild type mice. We also found that N-acetyl cysteine (NAC) could at least partially rescue the growth disadvantage of dyskerin mutant spleen cells or fibroblasts which was associated with accumulation of DNA damage and reactive oxygen species. To determine if NAC, or other antioxidants might be useful therapeutically it is important to determine their effects on stem cell function, which is defective in DC. To this end we established a cohort of mice that were given NAC in their drinking water (1mg/ml) from 3-weeks of age and maintained on NAC for 1 year. We found that long term NAC treatment did not show significant side effects on the mice. They had slightly increased neutrophils, but no difference in life span and body weight compared with the untreated group. Impressively, old male Dkc1Δ15 mice showed corrected B and T cell proportions in peripheral blood after treatment with NAC. Competitive bone marrow transplantation experiments were carried out in which a 1:1 mixture of BM cells from mutant and WT mice was used to repopulated lethally irradiated recipient mice. These experiments showed that, when taken from NAC treated animals, old Dkc1Δ15 BM cells could compete with age matched WT cells with 40–45% of Dkc1Δ15 cells in primary recipients compared with only 20% for the untreated group. Moreover, after secondary transplantation, cells from the NAC treated group still represent 15–20% of Dkc1Δ15 cells in recipients while those from the untreated group could not be detected. These results strongly suggest that NAC treatment can partially restore the bone marrow repopulating ability of Dkc1Δ15 stem cells. Together with our previous results these data suggest that a pathogenic Dkc1 mutation, through its effect on telomerase, initiates stem cell aging before telomeres are short and that increased oxidative stress might play a role in this process. Moreover the effects of the mutation may be prevented or delayed by antioxidant treatment, although the precise mechanism will be the subject of future investigation. Bessler:Alexion Pharmaceutical Inc:Consultancy;Novartis: Membership on an entity's Board of Directors or advisory committees; Taligen: Consultancy.
Author Gu, Baiwei
Bessler, Monica
Fan, Jian-meng
Mason, Philip J
Author_xml – sequence: 1
  givenname: Baiwei
  surname: Gu
  fullname: Gu, Baiwei
  organization: Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
– sequence: 2
  givenname: Jian-meng
  surname: Fan
  fullname: Fan, Jian-meng
  organization: Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
– sequence: 3
  givenname: Monica
  surname: Bessler
  fullname: Bessler, Monica
  organization: Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
– sequence: 4
  givenname: Philip J
  surname: Mason
  fullname: Mason, Philip J
  organization: Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
BookMark eNqFkMtOwzAURC1UJNrCN-AfSPArjy5DeVVqBYLC1nLtm2JI7cpOgf49acqezdy7mBmNzggNnHeA0CUlKaUlu1o13pv0jdI8ZTRlORW9nKAhzViZEMLIAA0JIXkiJgU9Q6MYPwihgrNsiNaVa63_sUa5Fi8DqHYD3fcMUe8g4srhSmtoIKgWDK7W1q3x0zs43-63gGcO3-zjJwTr8GLX9p7rbh5eqBD8N35pYYOn0DTxHJ3Wqolw8XfH6PXudjl9SOaP97NpNU80JblIKCsMV0VWTEoGinMhALgpMl5022vIDNRlrla1mpicC1YLRYlhjFAQK15owceoOPbq4GMMUMttsBsV9pISeeAle17ywEsyKg-oeumS1TEJ3bwvC0FGbcFpMDaAbqXx9t-OX6Tfd_M
ContentType Journal Article
Copyright 2010 American Society of Hematology
Copyright_xml – notice: 2010 American Society of Hematology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1182/blood.V116.21.2614.2614
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 2614
ExternalDocumentID 10_1182_blood_V116_21_2614_2614
S0006497119446818
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
9M8
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFFNX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N4W
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
AALRI
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFPUW
AIGII
AITUG
AKBMS
AKRWK
AKYEP
AMRAJ
CITATION
EFKBS
H13
ID FETCH-LOGICAL-c1064-127d3a757982ea3344ee3d7537497fe5def86abfa9d6342f4a10d2201e4b37c43
ISSN 0006-4971
IngestDate Wed Oct 01 03:04:11 EDT 2025
Fri Feb 23 02:43:41 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Language English
License This article is made available under the Elsevier license.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1064-127d3a757982ea3344ee3d7537497fe5def86abfa9d6342f4a10d2201e4b37c43
OpenAccessLink https://dx.doi.org/10.1182/blood.V116.21.2614.2614
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_V116_21_2614_2614
elsevier_sciencedirect_doi_10_1182_blood_V116_21_2614_2614
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-11-19
PublicationDateYYYYMMDD 2010-11-19
PublicationDate_xml – month: 11
  year: 2010
  text: 2010-11-19
  day: 19
PublicationDecade 2010
PublicationTitle Blood
PublicationYear 2010
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 1.9762558
Snippet Abstract 2614 X-linked Dyskeratosis Congenita (DC) is due to mutations in the DKC1 gene, which encodes the protein dyskerin. Dyskerin is a highly conserved...
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage 2614
Title Antioxidant Treatment Rescues An Accelerated Aging Phenotype In Dyskerin Mutated Bone Marrow Stem Cells
URI https://dx.doi.org/10.1182/blood.V116.21.2614.2614
Volume 116
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1528-0020
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014325
  issn: 0006-4971
  databaseCode: KQ8
  dateStart: 19460101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1528-0020
  dateEnd: 20241002
  omitProxy: true
  ssIdentifier: ssj0014325
  issn: 0006-4971
  databaseCode: DIK
  dateStart: 19460101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1528-0020
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014325
  issn: 0006-4971
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1528-0020
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014325
  issn: 0006-4971
  databaseCode: AKRWK
  dateStart: 19460101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKEIwXBB2I8Ut-QLxEKYnjOClvWQdah4oQ6tDeIjtxR0WXTjQVjP-D_5c720kzGBrjxUqj9JL4vpzP9nd3hLxIYyGZGApfzBLu86iET0rFYAxlwBNVCHB5McB58l4cHPHD4_i41_vZYS2tazUoflwaV_I_WoVzoFeMkr2GZluhcAKOQb_Qgoah_ScdZ0hV_D4voXe8acsY_6hXBRh7XO_LigKGFcwGUXqZKUf04bOulmbddVx5--erLxj-503Wtblmb1lhLSLMy4j8r1NvpBeL1YWN34WrLm9IO2u7ZTH_puctEOyK6iHAzofHOWnn--jSWnygHdkwhCbSBX3ZtR23T-UWIpDUEfrO3DXGVWDBOgsV7ewpJsAOWHDB4NroSocsGyDd2E9hQ0rdWNz8_NPOp5g31nD7B59A3oDBXB8uHmwEdDNr_zbitTxEMwNKWW4E5SgoZ2GOMkxzg9xkiRBYGGN__K7dnOIRs4Ux3Ps62iAIevWXJ7rc6ek4MtN75K6bgdDMwuk-6emqT3ayStbL03P6khpOsNls6ZNbe83R9qipDNgntyeOkLFDTjoQpC0EqYMgzSragSA1EKQtBOm4og0EqYMgRQhSC0GKEKQGgg_I0ds309GB72p3-EUIXq4fsqSMZBInw5RpGUWcax2VMDdOoMdmOi71LBVSzeSwFBHYAy7DoGQAK81VlBQ8eki2KrjhI0LBaQ2HmoErqzjnhVClUomKIw5GRgoR75Kg6dz8zKZoya9Q7C553Sghd56m9SBzANhVf358_fs9IXc2X8xTslV_Xetn4MzW6rmB1i_4fpiG
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antioxidant+Treatment+Rescues+An+Accelerated+Aging+Phenotype+In+Dyskerin+Mutated+Bone+Marrow+Stem+Cells&rft.jtitle=Blood&rft.au=Gu%2C+Baiwei&rft.au=Fan%2C+Jian-meng&rft.au=Bessler%2C+Monica&rft.au=Mason%2C+Philip+J&rft.date=2010-11-19&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=116&rft.issue=21&rft.spage=2614&rft.epage=2614&rft_id=info:doi/10.1182%2Fblood.V116.21.2614.2614&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_V116_21_2614_2614
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon